Irbesartan/Hydrochlorothiazide Sandoz

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartan/Hydrochlorothiazide Sandoz, are an angiotensin II receptor blocker and a thiazide diuretic presented as oral tablets for oral use. The combination provides complementary mechanisms to achieve blood pressure control in adults with hypertension.

GNH USA supplies Irbesartan/Hydrochlorothiazide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU marketing authorisation standards and is manufactured under strict quality guidelines.

Irbesartan/Hydrochlorothiazide is used to treat hypertension, a condition characterised by persistently elevated arterial pressure.

- Essential hypertension: reduces systolic and diastolic pressure by blocking angiotensin II and promoting sodium excretion. - Secondary hypertension: assists in controlling blood pressure when an underlying cause is present, as part of a broader therapeutic regimen.

Irbesartan/Hydrochlorothiazide may cause a range of adverse reactions, which are categorised by frequency.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Increased urinary frequency. - Mild electrolyte disturbances (e.g., low potassium).

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance. - Acute kidney injury or worsening renal function. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Marked hypotension leading to fainting or shock.

Before initiating therapy, consider the following precautions.

- Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte monitoring: check potassium and sodium levels, especially in patients on other diuretics. - Hepatic impairment caution: dose adjustment may be required in severe liver disease. - Severe hypotension avoidance: avoid rapid posture changes and monitor blood pressure closely. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide can interact with several medicines; clinical judgment is required.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalaemia. - ACE inhibitors or ARBs combined with aliskiren in diabetic patients: increased renal risk. - Lithium: may raise lithium concentrations and toxicity. - NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering may cause bradycardia. - Calcium‑channel blockers: may enhance hypotensive response. - Antidiabetic agents: blood‑glucose control may improve, requiring dose adjustment.